Neurodegenerative diseases

This page brings together the European Medicines Agency's (EMA) latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis. It lists:

the newest and most recently updated medicines authorised for the treatment of neurodegenerative diseases in the European Union (EU);
any recent opinions on medicines for neurodegenerative diseases that are pending authorisation by the European Commission (EC);
EMA's latest news announcements related to neurodegenerative diseases;
EMA's events on topics related to neurodegenerative diseases.

Neurodegenerative diseases

New and recently updated medicines

Rilutek (Authorised)

Neuraceq (Authorised)

Vyvgart (Authorised)

Prometax (Authorised)

Raxone (Authorised)

Latest news

EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

First gene therapy to treat severe haemophilia A

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022

First therapy to treat two types of Niemann-Pick disease, a rare genetic metabolic disorder

First therapy to treat rare genetic nervous system disorder AADC deficiency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021

Events of interest

Multi-stakeholder workshop on the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders

Multiple sclerosis workshop - Registries initiative

Spinal muscular atrophy workshop

Workshop on clinical outcome measures and endpoints for efficacy assessment in spinal muscular atrophy